NOVAVAX (NVAX)
EARNINGS RELEASE - AUGUST 10 (AMC)
EARNINGS EXPECTATIONS:
THIS QTR: EPS: -.42/share REV: 39.58/M
___________________________________________________________
LAST QTR: EPS: -.70/share ACTUAL: -.58/share (BEAT)
____________________________________________________________
NEXT QTR: EPS: 1.35/share REV: 234.3/M
____________________________________________________________
FULL YR: EPS: 7.97/share REV: 1,100/M
____________________________________________________________
BEAT/MISS RECORD: 35% OF THE TIME THEY BEAT ESTIMATES
PRIOR ‘JUMP ZONE’ MOVES (LAST 3 QTRS %) 83.4, -12.9, 7.77
EXPECTED JUMP MOVE THIS QUARTER: 15-20%
——–
*** With market volatility at extremes there is greater risk in trading these events which may not react as they would under normal market conditions. Please take extra caution before tradin
Links To Latest News and Headlines
Coronavirus vaccine stocks were the biggest investment theme of 2020. Since, two biotech companies — Moderna (NASDAQ: MRNA) and BioNTech — actually have commercialized their vaccines. Let’s take a look at where they’re at with vaccine programs — and whether they’re on track to beat the market in the second half.
Moderna (NASDAQ: MRNA), Johnson & Johnson (NYSE: JNJ), and Pfizer (NYSE: PFE) and its partner BioNTech (NASDAQ: BNTX) share the U.S. COVID-19 vaccine market right now. In this Motley Fool Live video recorded on July 21, healthcare and cannabis bureau editor-analyst Olivia Zitkus and Motley Fool contributor Keith Speights discuss how Novavax (NASDAQ: NVAX) could potentially shake up the COVID vaccine market.
Dr. Michael Gonzalez, Emergency Medicine Physician & Assistant Professor at Baylor College of Medicine, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
With Covid-19 vaccination rates slowing around the world, now is not the time to buy biotechnology company Novavax (NASDAQ:NVAX) stock. Source: Ascannio/Shutterstock.com NVAX stock fell 10% between July 20 and July 27 as hope fades that the company will be able to get its Covid-19 vaccine to market in time to capitalize on demand for immunization against the deadly respiratory disease. Novavax’s share price has now declined 23% since the end of April and is 37% below its 52-week high reached in
Novavax (NVAX) doesn’t possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
StockJumpers analysis and trade plans are finalized and uploaded generally one house before market cloase (3PM EST) for most events unless noticed.
“I’m sorry, this content is for members only. To access this content, you must log in with your membership credentials – OR if you are not a member yet, visit our registration page here and get signed up Looking forward to having you on-board ASAP”
There is a significant amount of data behind the scenes involved in the analysis and trade plan tab above, that does not get put into the report. Too much information for traders often confuses things – so this is stripped down to only what is needed to make the best possible decision(s) on trading the trajectory.
Members who are too busy to manual trade can use Trade Assist. For more information visit here
| Avg Daily Volume: 8,831,772 Market Cap: 5.65B Sector: Healthcare Short Interest: 13.87 |
Ticker delayed 20 minutes
NOTICE: All material on this site has been published for informational and educational purposes only and does not constitute an offer to sell nor a solicitation of an offer to buy any security which may be referenced here or in our websites. StockJumpers is not an Investment Adviser and relies on the publisher’s exemption as defined in Section 401(f) of the Uniform Securities Act, and provides no personal advice or recommendations. The services and published information contained herein is for non-commercial, educational use and display. StockJumpers and any of its affiliates does not represent that the securities or services discussed are suitable for any investor. You should assume that StockJumpers and or its management has or will take a position in the stock, whether it is stated or not. You are further advised not to rely on any information contained in this report and associated websites in the process of making a fully informed investment decision. Trading is risky and you can lose your investment. For the complete risk disclosure and other legal information please review the full Terms of Use Agreement.
by Team Stockjumpers